Bluejay Diagnostics (BJDX) Cash & Current Investments (2020 - 2026)

Bluejay Diagnostics has disclosed Cash & Current Investments across 7 years of filings, most recently posting $3.7 million for Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $3.7 million, up 18.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.7 million (up 18.24% YoY), and the FY2025 annual result was $5.2 million, up 20.06% from the prior year.
• Cash & Current Investments came in at $3.7 million for Q1 2026 at Bluejay Diagnostics, down from $5.2 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $17.1 million in Q1 2022 to a low of $2.2 million in Q4 2023.
• The 5-year median for Cash & Current Investments is $5.1 million (2023), against an average of $6.8 million.
• Across the five-year window, Cash & Current Investments surged 470.33% in 2022 and slumped 78.17% in 2023, its largest moves.
• Bluejay Diagnostics' Cash & Current Investments stood at $10.1 million in 2022, then plunged by 78.17% to $2.2 million in 2023, then soared by 94.79% to $4.3 million in 2024, then gained by 20.06% to $5.2 million in 2025, then decreased by 28.66% to $3.7 million in 2026.
• The last three Cash & Current Investments figures came in at $3.7 million (Q1 2026), $5.2 million (Q4 2025), and $3.1 million (Q3 2025), per Business Quant data.